Without adequate power, that 24% reduction is not
Post# of 148288
(Total Views: 736)
Posted On: 03/06/2021 12:03:05 AM
Without adequate power, that 24% reduction is not a reliable number. Based on statistics, with such a low power, leronlimab could have reduced mortality by 23% partially due to chance. Sorry but that's just how the FDA will view the numbers. Janet Woodcock has continually reinforced that they are interested in adequately powered trials.
(2)
(3)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼